
Beam Therapeutics (BEAM) Stock Forecast & Price Target
Beam Therapeutics (BEAM) Analyst Ratings
Bulls say
Beam Therapeutics is supported by a compelling clinical and regulatory inflection in risto-cel, which met the pivotal BEACON trial’s primary endpoint of freedom from severe VOCs for ≥12 consecutive months, along with all primary safety and secondary efficacy endpoints, while safety remained consistent with prior data. The program’s profile is further strengthened by prior results showing mean HbF of 63.5% at Month 6 and rapid engraftment signals, and the company ended 3Q26 with $1.0B in cash and equivalents plus an additional $200MM expected from its Sixth Street facility, providing runway into mid-2029. Beyond SCD, the broader pipeline across BEAM-302, BEAM-304, and BEAM-301 adds multiple shots on goal, with updated BEAM-302 data showing durable biomarker improvements and basket BLA guidance potentially streamlining development in monogenic diseases.
Bears say
Beam Therapeutics is exposed to substantial fundamental risk because its valuation depends heavily on early-stage gene-editing programs that could suffer from poorer-than-expected preclinical or clinical data, off-target activity, or other safety signals. The company also faces meaningful regulatory and commercialization uncertainty, since novel medicines may require additional or longer-term data, may not gain approval, and may struggle to achieve favorable reimbursement or adoption. In addition, greater-than-expected competition, intellectual property risk, and negative industry headlines could materially reduce each product candidate’s market potential and limit long-term value creation.
This aggregate rating is based on analysts' research of Beam Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Beam Therapeutics (BEAM) Analyst Forecast & Price Prediction
Start investing in Beam Therapeutics (BEAM)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Beam Therapeutics (BEAM) Forecast
Beam Therapeutics (BEAM) Analyst Forecast & Price Prediction
Start investing in Beam Therapeutics (BEAM)
Order type
Buy in
Order amount
Est. shares
0 shares